<DOC>
	<DOCNO>NCT02207686</DOCNO>
	<brief_summary>The investigator aim analyze tumor vHL patient different course disease different type VHL gene alteration characterize type genetic alteration tumor contain alteration affect tumor cell ' behavior molecular level . The investigator compare observation vHL disease outcome patient family . It already know vHL tumor develop copy VHL gene cell inactivate . The first copy inactivate person 's cell birth ( `` first hit '' ) , leave one functional copy . A tumor develop cell second copy also inactivate ( `` second hit '' ) . So far , molecular consequence first hit investigate . It hypothesis first second hit combination consequence tumor development clinical outcome . The investigator include tumor patient different disease course different type `` first hit '' analyse tumor ' DNA order find correlation first second hit patient ' family ' medical history . The investigator hereby hope give new insight vHL tumor grow genetic factor influence tumor development . These result contribute current knowledge vHL help u get one step closer able predict individual 's tumor risk need surveillance .</brief_summary>
	<brief_title>Assessment Residual VHL Function Tumors - Can Predict Patients ' Individual Course Disease ?</brief_title>
	<detailed_description>In vHL tumor patient different phenotype different genetic background , investigator aim assess nature germline somatic VHL mutation along total residual VHL protein ( pVHL ) activity tumor cell evaluate association disease outcome patient family . vHL tumor development follow Knudson 's `` two-hit-mode '' : patient bear germline mutation one copy VHL gene cell body - `` first hit '' . Somatic mutation copy VHL gene - `` second hit '' - initiate tumor development . Pheno-genotype correlation well know vHL , far explain exclusively nature germline mutation ( first hit ) . It investigators ' hypothesis total residual activity protein ( pVHL ) present tumor first second hit , decide tumor 's destiny . The investigator apply Sanger sequencing , MLPA ( multiplex ligation dependent probe amplification ) , LOH ( Loss heterogeneity ) analysis , methylation assay , FISH ( Fluorescence In Situ Hybridization ) , immunohistochemistry characterize germline somatic mutation , determine presence mRNA pVHL , assess residual VHL activity tumor . All method already establish laboratory . The result give deep insight vHL tumorigenesis pave road future individual prediction patientÂ´s course disease need surveillance .</detailed_description>
	<mesh_term>Von Hippel-Lindau Disease</mesh_term>
	<criteria>vHL diagnose patient Patient 18 year age Informed consent participate obtain Patient least one vHLrelated tumor remove A reference DNA sample ( blood normal tissue ) tumor tissue ( paraffinembedded fresh frozen ) obtain . Patients age 18 year Patients previously vHLrelated tumor remove Patients whos previously remove tumor tissue obtain quantity quality exact histological analysis do and/or DNA extract</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>CNS hemangioblastoma</keyword>
	<keyword>Renal Cell Carcinoma</keyword>
	<keyword>VHL germline mutation</keyword>
	<keyword>VHL somatic mutation</keyword>
	<keyword>Tumor development</keyword>
</DOC>